These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1961 related items for PubMed ID: 21828397

  • 1. Comparison of six-year clinical outcome of sirolimus- and paclitaxel-eluting stents to bare-metal stents in patients with ST-segment elevation myocardial infarction: an analysis of the RESEARCH (rapamycin-eluting stent evaluated at Rotterdam cardiology hospital) and T-SEARCH (taxus stent evaluated at Rotterdam cardiology hospital) registries.
    Simsek C, Magro M, Boersma E, Onuma Y, Nauta S, Daemen J, Gaspersz M, van Geuns RJ, van der Giessen W, van Domburg R, Serruys P.
    J Invasive Cardiol; 2011 Aug; 23(8):336-41. PubMed ID: 21828397
    [Abstract] [Full Text] [Related]

  • 2. The unrestricted use of sirolimus- and paclitaxel-eluting stents results in better clinical outcomes during 6-year follow-up than bare-metal stents: an analysis of the RESEARCH (Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital) and T-SEARCH (Taxus-Stent Evaluated At Rotterdam Cardiology Hospital) registries.
    Simsek C, Magro M, Boersma E, Onuma Y, Nauta ST, Gaspersz MP, van der Giessen WJ, van Domburg RT, Serruys PW, Interventional Cardiologists of the Thoraxcenter.
    JACC Cardiovasc Interv; 2010 Oct; 3(10):1051-8. PubMed ID: 20965464
    [Abstract] [Full Text] [Related]

  • 3. Four-year clinical outcome of sirolimus- and paclitaxel-eluting stents compared to bare-metal stents for the percutaneous treatment of stable coronary artery disease.
    Simsek C, Onuma Y, Magro M, de Boer S, Battes L, van Domburg RT, Boersma E, Serruys PW, Interventional Cardiologists of the Thoraxcenter (2000-2005).
    Catheter Cardiovasc Interv; 2010 Jul 01; 76(1):41-9. PubMed ID: 20310019
    [Abstract] [Full Text] [Related]

  • 4. Comparison of three-year clinical outcome of sirolimus- and paclitaxel-eluting stents versus bare metal stents in patients with ST-segment elevation myocardial infarction (from the RESEARCH and T-SEARCH Registries).
    Daemen J, Tanimoto S, García-García HM, Kukreja N, van de Sande M, Sianos G, de Jaegere PP, van Domburg RT, Serruys PW.
    Am J Cardiol; 2007 Apr 15; 99(8):1027-32. PubMed ID: 17437722
    [Abstract] [Full Text] [Related]

  • 5. Long-term outcome of the unrestricted use of everolimus-eluting stents compared to sirolimus-eluting stents and paclitaxel-eluting stents in diabetic patients: the Bern-Rotterdam diabetes cohort study.
    Simsek C, Räber L, Magro M, Boersma E, Onuma Y, Stefanini GG, Zanchin T, Kalesan B, Wenaweser P, Jüni P, van Geuns RJ, van Domburg RT, Windecker S, Serruys PW.
    Int J Cardiol; 2013 Dec 05; 170(1):36-42. PubMed ID: 24196314
    [Abstract] [Full Text] [Related]

  • 6. Long-Term outcome of drug-eluting stents compared with bare metal stents in ST-segment elevation myocardial infarction: results of the paclitaxel- or sirolimus-eluting stent versus bare metal stent in Primary Angioplasty (PASEO) Randomized Trial.
    Di Lorenzo E, Sauro R, Varricchio A, Carbone G, Cortese G, Capasso M, Lanzillo T, Manganelli F, Mariello C, Siano F, Pagliuca MR, Stanco G, Rosato G, De Luca G.
    Circulation; 2009 Sep 15; 120(11):964-72. PubMed ID: 19720939
    [Abstract] [Full Text] [Related]

  • 7. Long-term outcome after drug eluting stenting in patients with ST-segment elevation myocardial infarction: data from the REAL registry.
    Campo G, Saia F, Percoco G, Manari A, Santarelli A, Vignali L, Varani E, Benassi A, Sangiorgio P, Tarantino F, Magnavacchi P, De Palma R, Guastaroba P, Marzocchi A.
    Int J Cardiol; 2010 Apr 15; 140(2):154-60. PubMed ID: 19056134
    [Abstract] [Full Text] [Related]

  • 8. Primary percutaneous coronary intervention for acute myocardial infarction: long-term outcome after bare metal and drug-eluting stent implantation.
    Kukreja N, Onuma Y, Garcia-Garcia H, Daemen J, van Domburg R, Serruys PW.
    Circ Cardiovasc Interv; 2008 Oct 15; 1(2):103-10. PubMed ID: 20031664
    [Abstract] [Full Text] [Related]

  • 9. 5-year follow-up after primary percutaneous coronary intervention with a paclitaxel-eluting stent versus a bare-metal stent in acute ST-segment elevation myocardial infarction: a follow-up study of the PASSION (Paclitaxel-Eluting Versus Conventional Stent in Myocardial Infarction with ST-Segment Elevation) trial.
    Vink MA, Dirksen MT, Suttorp MJ, Tijssen JG, van Etten J, Patterson MS, Slagboom T, Kiemeneij F, Laarman GJ.
    JACC Cardiovasc Interv; 2011 Jan 15; 4(1):24-9. PubMed ID: 21251625
    [Abstract] [Full Text] [Related]

  • 10. Maintenance of long-term clinical benefit with sirolimus-eluting stents in patients with ST-segment elevation myocardial infarction 3-year results of the SESAMI (sirolimus-eluting stent versus bare-metal stent in acute myocardial infarction) trial.
    Violini R, Musto C, De Felice F, Nazzaro MS, Cifarelli A, Petitti T, Fiorilli R.
    J Am Coll Cardiol; 2010 Feb 23; 55(8):810-4. PubMed ID: 20170821
    [Abstract] [Full Text] [Related]

  • 11. Long-term effects of drug-eluting stents versus bare metal stents on patients with acute ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: outcomes of 3-year clinical follow-up.
    Wang CH, Fang Q, Zhang SY, Shen ZJ, Fan ZJ, Jin XF, Zeng Y, Liu ZY, Xie HZ, Yang M.
    Chin Med J (Engl); 2012 Aug 23; 125(16):2803-6. PubMed ID: 22932070
    [Abstract] [Full Text] [Related]

  • 12. Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials.
    Bangalore S, Kumar S, Fusaro M, Amoroso N, Attubato MJ, Feit F, Bhatt DL, Slater J.
    Circulation; 2012 Jun 12; 125(23):2873-91. PubMed ID: 22586281
    [Abstract] [Full Text] [Related]

  • 13. The unrestricted use of paclitaxel- versus sirolimus-eluting stents for coronary artery disease in an unselected population: one-year results of the Taxus-Stent Evaluated at Rotterdam Cardiology Hospital (T-SEARCH) registry.
    Ong AT, Serruys PW, Aoki J, Hoye A, van Mieghem CA, Rodriguez-Granillo GA, Valgimigli M, Sonnenschein K, Regar E, van der Ent M, de Jaegere PP, McFadden EP, Sianos G, van der Giessen WJ, de Feyter PJ, van Domburg RT.
    J Am Coll Cardiol; 2005 Apr 05; 45(7):1135-41. PubMed ID: 15808774
    [Abstract] [Full Text] [Related]

  • 14. 5-year clinical outcomes after sirolimus-eluting stent implantation insights from a patient-level pooled analysis of 4 randomized trials comparing sirolimus-eluting stents with bare-metal stents.
    Caixeta A, Leon MB, Lansky AJ, Nikolsky E, Aoki J, Moses JW, Schofer J, Morice MC, Schampaert E, Kirtane AJ, Popma JJ, Parise H, Fahy M, Mehran R.
    J Am Coll Cardiol; 2009 Sep 01; 54(10):894-902. PubMed ID: 19712798
    [Abstract] [Full Text] [Related]

  • 15. Comparison of long-term clinical outcome after successful implantation of Firebird sirolimus- and Taxus paclitaxel-eluting stents in Chinese population: analysis of a large single center registry.
    Dou KF, Xu B, Yang YJ, Chen JL, Qiao SB, Wang Y, Li JJ, Qin XW, Yao M, Liu HB, Wu YJ, Chen J, Yuan JQ, You SJ, Li W, Gao RL.
    Chin Med J (Engl); 2010 Apr 05; 123(7):810-5. PubMed ID: 20497669
    [Abstract] [Full Text] [Related]

  • 16. Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY).
    Valgimigli M, Tebaldi M, Borghesi M, Vranckx P, Campo G, Tumscitz C, Cangiano E, Minarelli M, Scalone A, Cavazza C, Marchesini J, Parrinello G, PRODIGY Investigators.
    JACC Cardiovasc Interv; 2014 Jan 05; 7(1):20-8. PubMed ID: 24332420
    [Abstract] [Full Text] [Related]

  • 17. Benefits of drug-eluting stents as compared to bare metal stent in ST-segment elevation myocardial infarction: four year results of the PaclitAxel or Sirolimus-Eluting stent vs bare metal stent in primary angiOplasty (PASEO) randomized trial.
    Di Lorenzo E, Sauro R, Varricchio A, Capasso M, Lanzillo T, Manganelli F, Mariello C, Siano F, Pagliuca MR, Stanco G, Rosato G, De Luca G.
    Am Heart J; 2009 Oct 05; 158(4):e43-50. PubMed ID: 19781402
    [Abstract] [Full Text] [Related]

  • 18. Clinical outcomes with drug-eluting and bare-metal stents in patients with ST-segment elevation myocardial infarction: evidence from a comprehensive network meta-analysis.
    Palmerini T, Biondi-Zoccai G, Della Riva D, Mariani A, Sabaté M, Valgimigli M, Frati G, Kedhi E, Smits PC, Kaiser C, Genereux P, Galatius S, Kirtane AJ, Stone GW.
    J Am Coll Cardiol; 2013 Aug 06; 62(6):496-504. PubMed ID: 23747778
    [Abstract] [Full Text] [Related]

  • 19. The everolimus-eluting stent in real-world patients: 6-month follow-up of the X-SEARCH (Xience V Stent Evaluated at Rotterdam Cardiac Hospital) registry.
    Onuma Y, Kukreja N, Piazza N, Eindhoven J, Girasis C, Schenkeveld L, van Domburg R, Serruys PW, Interventional Cardiologists of the Thoraxcenter (2000 to 2007).
    J Am Coll Cardiol; 2009 Jul 14; 54(3):269-76. PubMed ID: 19589442
    [Abstract] [Full Text] [Related]

  • 20. Long-term safety and efficacy with paclitaxel-eluting stents: 5-year final results of the TAXUS IV clinical trial (TAXUS IV-SR: Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent).
    Ellis SG, Stone GW, Cox DA, Hermiller J, O'Shaughnessy C, Mann T, Turco M, Caputo R, Bergin PJ, Bowman TS, Baim DS, TAXUS IV Investigators.
    JACC Cardiovasc Interv; 2009 Dec 14; 2(12):1248-59. PubMed ID: 20129552
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 99.